SCHEMBL5016519

SCHEMBL5016519

NC1(S(=O)(=O)O)CC=Cc2ccccc21

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
OXTR P30559 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9765523 0.80 OPRM1 (0.33)
SCHEMBL1419070 0.78 THRB (0.32) OXTR
SCHEMBL11048808 0.78 CDK2 (0.31)
SCHEMBL9292945 0.77 HSD11B1 (0.32) OXTR
SCHEMBL27594815 0.77 OXTR (0.33) OXTR
SCHEMBL11618189 0.77 THRB (0.32) OXTR
SCHEMBL11618195 0.77 OXTR (0.33) TSHRSMN1; SMN2OXTR
SCHEMBL11667979 0.77 OXTR (0.31) OXTR
SCHEMBL29240831 0.76
SCHEMBL27415320 0.76 TTR (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365223-B2 Method for selective targeting of apoptotic cells and small molecule ligands used thereof NST NEUROSURVIVAL TECHNOLOGIES LTD (IL) 2008-04-29 US disclosed
US-20060160901-A1 Method for selective targeting of apoptotic cells and small molecule ligands used thereof APOSENSE LTD. (IL) 2006-07-20 US disclosed
EP-1643958-A2 METHOD FOR SELECTIVE TARGETING OF APOPTOTIC CELLS AND SMALL MOLECULE LIGANDS USED THEREOF NST Neurosurvival Technologies Ltd. (IL) 2006-04-12 EP disclosed
WO-2004110339-A2 METHOD FOR SELECTIVE TARGETING OF APOPTOTIC CELLS AND SMALL MOLECULE LIGANDS USED THEREOF NST NEUROSURVIVAL TECHNOLOGIES LTD. (IL) 2004-12-23 WO disclosed
US-5248335-A Low viscosity ink TOYO INK MANUFACTURING CO., LTD. (JP) 1993-09-28 US disclosed
US-5144014-A Process for production of monoazo lake coated with water-insoluble metal salt of rosin TOYO INK MANUFACTURING CO., LTD. (JP) 1992-09-01 US disclosed
US-5079347-A Fiber reactive dyes for wool and cellulose HOECHST AKTIENGESELLSCHAFT (DE) 1992-01-07 US disclosed
EP-0214545-B1 PROCESS FOR THE PREPARATION OF 1-AMINONAPHTHALENE-2,4,7-TRISULFONIC ACID AND 1-AMINONAPHTHALENE-7-SULFONIC ACID BAYER AG (DE) 1991-11-27 EP disclosed
US-4836959-A SULFONATION OF 1-AMINONAPHTHALENE OR NAPHTHOIC ACID BAYER AKTIENGSELLSCHAFT (DE) 1989-06-06 US disclosed
US-4091013-A Process for preparing 1-amino-naphthalene-7-sulphonic acid BAYER AKTIENGESELLSCHAFT (DT) 1978-05-23 US disclosed
US-4081439-A Aromatic disazo pigments CIBA-GEIGY CORPORATION (US) 1978-03-28 US disclosed
US-4062838-A LACQUERS, PRINTING INKS, YELLOW TO ORANGE CIBA-GEIGY CORPORATION (US) 1977-12-13 US disclosed
US-4055559-A ACETYLACETANILIDO CIBA-GEIGY CORPORATION (US) 1977-10-25 US disclosed
US-3988312-A TETRAKISAZO DYES CIBA-GEIGY CORPORATION (US) 1976-10-26 US disclosed
US-3978038-A POLYAMIDES, POLYESTERS, POLYURETHANES CIBA-GEIGY CORPORATION (US) 1976-08-31 US disclosed
US-3956266-A DISAZO DYES CIBA-GEIGY CORPORATION (US) 1976-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160901-A1 Method for selective targeting of apoptotic cells and small molecule ligands used thereof BAD, BAX, CASP3 TSHR 2988/4885SMN1; SMN2 3886/4885OXTR 2917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.